Abstract | BACKGROUND: The purpose of this study was to retrospectively analyze the pattern and the management of recurrence of rectal cancer treated with 22-fraction intensity-modulated radiation therapy (IMRT). PATIENTS AND METHODS: This study included patients who underwent IMRT with gross tumor volume of 50.6 Gy in 22 fractions with concurrent capecitabine treatment over a period of 30 days, after which the patients underwent total mesorectal excision at Peking University Cancer Hospital (2007-2015). Study end points were local recurrence-free survival (LRFS), local disease-free survival (LDFS), disease-free survival (DFS), and cancer-specific survival (CSS). RESULTS: A total of 687 patients were included in our analysis. The median age was 57 years (range, 21-87 years), and 66.4% of the patients were male. The estimated 5-year LRFS and 5-year LDFS rates were 94.4% (95% confidence interval [CI], 92.1%-96.7%) and 96.1% (95% CI, 94.1%-98.1%), respectively. The estimated 3-year DFS and 5-year CSS rates were 77.5% (95% CI, 74.1%-80.9%) and 84.7% (95% CI, 80.9%-88.4%), respectively. Overall, 33.3% of patients (9 of 27) who developed local recurrence, 35.8% of patients (19 of 53) who developed lung metastasis, and 60% of patients (15 of 25) who developed liver metastasis received curative treatment after recurrence. The estimated 3-year survival after recurrence rates of patients who received curative versus palliative treatment were significantly different (87.8% vs. 15.3%, P = .000). CONCLUSION:
Rectal cancer treated with the 22-fraction IMRT regimen provides good local control. More than one-fourth of patients who develop recurrence have the chance to receive curative treatment with the incorporation of a multidisciplinary team and achieves excellent survival after recurrence.
|
Authors | Ai-Wen Wu, Yong Cai, Yong-Heng Li, Lin Wang, Zhong-Wu Li, Ying-Shi Sun, Jia-Fu Ji |
Journal | Clinical colorectal cancer
(Clin Colorectal Cancer)
Vol. 17
Issue 2
Pg. e307-e313
(06 2018)
ISSN: 1938-0674 [Electronic] United States |
PMID | 29525524
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2018 Elsevier Inc. All rights reserved. |
Chemical References |
- Antineoplastic Agents
- Capecitabine
|
Topics |
- Adenocarcinoma
(mortality, radiotherapy, secondary)
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(administration & dosage)
- Capecitabine
(administration & dosage)
- Chemoradiotherapy
(methods)
- Disease-Free Survival
- Female
- Humans
- Kaplan-Meier Estimate
- Liver Neoplasms
(secondary, surgery)
- Lung Neoplasms
(secondary, surgery)
- Male
- Middle Aged
- Neoadjuvant Therapy
(methods)
- Neoplasm Metastasis
(pathology, therapy)
- Neoplasm Recurrence, Local
(mortality, pathology, therapy)
- Radiotherapy, Intensity-Modulated
(methods)
- Rectal Neoplasms
(mortality, pathology, radiotherapy)
- Retrospective Studies
- Young Adult
|